PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31470364-8	2020	In this study, we identified that RAW264.7 preosteoclast cells treated with proteasome inhibitor (MG-132) suppress RANK receptor expression essential for OCL differentiation, but no effect on TRAF-6.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	98-104	occludin	Mus musculus	154-157	
31470364-16	2020	In-addition, mouse bone marrow cultures treated with MG-132 suppress OCL formation and bone resorption activity.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	53-59	occludin	Mus musculus	69-72	
31415587-8	2019	In addition, MMP-9 activity and occludin degradation were reduced because of MG132 treatment.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	77-82	occludin	Mus musculus	32-40